Scientists identify breast cancer patients who may develop incurable secondary cancers

January 9, 2018, King's College London

Scientists from King's College London, funded by Breast Cancer Now, believe they have found a way to identify lymph-node positive breast cancer patients who are most likely to develop incurable secondary tumours (metastases) and those who are less at risk. The research is published today in The Journal of Pathology: Clinical Research.

Currently, when a patient is diagnosed with breast cancer, doctors investigate whether have already spread to some of their lymph nodes (known as lymph-node positive breast cancer). Patients with lymph-node positive disease tend to experience worse outcomes, and are therefore normally given more intensive treatment, such as chemotherapy.

In the new study, scientists at King's College London, led by Dr Anita Grigoriadis from the Breast Cancer Now Research Unit at King's College London, studied lymph node tissue and primary tumour samples from 309 , who were treated between 1984 and 2002 at Guy's Hospital London.

As part of the research scientists looked at both positive (presence of cancer cells), and negative (free of cancer cells) lymph-nodes. Crucially, they found that it is the features of the cancer-free lymph nodes that may add valuable information to help predict the likelihood of the disease spreading.

By applying sophisticated mathematical models, researchers were able to analyse morphological changes of the lymph nodes and develop a score to predict an individual's risk of breast cancer spread. Of the whose lymph node status was known, 143 had cancer cells present in their lymph nodes and were therefore thought to have a higher risk of developing cancer in distant organs.

The study found that within this high risk group, around a quarter of women were in fact unlikely to develop metastasis within ten years. Early results showed that variances in the architectural features of cancer-free lymph nodes could help doctors differentiate between patients that are more or less likely to develop secondary cancers.

If validated in larger studies, this breakthrough could mean that it may be possible to identify those at the highest risk of their breast cancer spreading, with more aggressive treatments targeted specifically to them, while those at low risk could be spared treatments that may not benefit them, as well as the subsequent side-effects.

Speaking about the research Dr Anita Grigoriadis said: "At present the tissue of breast cancer patients is routinely investigated to determine if the cancer has spread to the lymph node. This new interdisciplinary research including pathologists, mathematicians and bioinformaticians, suggests that there is a need to get ahead of the 'cancer curve' and identify other markers whose presence suggests that cancer may develop.

"With our method, we utilise tissue which is used routinely for diagnosis of breast cancer patients. By inspecting more features of the lymph node, we can separate the lymph-node positive breast cancer patients into a group who will develop distant metastasis quickly, and identify those patients who have very little risk of getting secondary cancers. We can therefore provide crucial information and might identify low-risk patients among a high-risk group."

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, which funded the study said: "That analysing the architecture of could help predict whose breast cancer is likely to spread, and ultimately help guide treatment, is a highly exciting prospect. If we are to finally stop people dying from breast , we need to find ways to prevent the disease from spreading around the body, where it becomes incurable.

"Patients' tumours can vary significantly in their biology over time. A new score that could identify certain women with primary in need of more or less aggressive treatments could play a pivotal role in ensuring they are given the best possible chance of survival, while only giving treatments such as chemotherapy when it's necessary.

"Importantly, as this tissue is already routinely taken at surgery, this analysis could in theory be easily integrated into current diagnostic tools, with further validation now needed in larger groups."

Explore further: Less invasive surgery detects residual breast cancer in lymph nodes after chemotherapy

More information: The paper - 'Histological scoring of immune and stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph node-positive cancers' is published in The Journal of Pathology: Clinical Research.

Related Stories

Less invasive surgery detects residual breast cancer in lymph nodes after chemotherapy

December 5, 2012
Most patients whose breast cancer has spread to their lymph nodes have most of the lymph nodes in their armpit area removed after chemotherapy to see if any cancer remains. A study conducted through the American College of ...

Which breast cancer patients need lymph nodes removed? Ultrasound narrows it down

February 2, 2015
Which breast cancer patients need to have underarm lymph nodes removed? Mayo Clinic-led research is narrowing it down. A new study finds that not all women with lymph node-positive breast cancer treated with chemotherapy ...

Some breast cancer patients on neoadjuvant chemo may avoid axillary lymph node dissection

December 7, 2016
A sentinel lymph node biopsy (SLNB) during surgery that showed no signs of cancer was associated with a low risk for breast cancer recurrence in the axillary (armpit) lymph nodes for patients with large, operable breast tumors ...

Study in early stage breast cancer shows that even small tumors can be aggressive

September 3, 2017
Even small tumours can be aggressive, according to a study in patients with early stage breast cancer that will be presented at the ESMO 2017 Congress in Madrid. (1) Researchers found that nearly one in four small tumours ...

Sentinel lymph node dissection non-inferior to axillary node

September 13, 2017
(HealthDay)—Ten-year overall survival for primary breast cancer patients treated with sentinel lymph node dissection (SLND) alone is similar to that seen in those treated with axillary lymph node dissection (ALND), according ...

Additional radiation reduces breast-cancer recurrence for some patients

July 22, 2015
A study has found no increase in overall survival but a reduction in breast cancer recurrence when additional radiation is given to the lymph nodes as well as the standard treatment of whole-breast irradiation after breast-conserving ...

Recommended for you

Scientists discover how breast cancer hibernates: study

May 22, 2018
Scientists have identified the mechanism that allows breast cancer cells to lie dormant in other parts of the body only to reemerge years later with lethal force, according to a study published Tuesday.

Researcher: Big data, networks identify cell signaling pathways in lung cancer

May 22, 2018
A team of scientists led by University of Montana cell biologist Mark Grimes has identified networks inside lung cancer cells that will help understand this cancer and fight it with drug treatments.

Resetting the epigenetic balance for cancer therapy

May 22, 2018
Though mutations in a gene called MLL3 are common across many types of cancers, their relationship to the development of the disease has been unclear. Now, a Northwestern Medicine study has identified an epigenetic imbalance ...

Downward-facing mouse: Stretching reduces tumor growth in mouse model of breast cancer

May 22, 2018
Many cancer patients seek out gentle, movement-based stretching techniques such as yoga, tai chi and qigong, but does stretching have an effect on cancer? While many animal studies have attempted to quantify the effects of ...

Compound in citrus oil could reduce dry mouth in head, neck cancer patients

May 21, 2018
A compound found in citrus oils could help alleviate dry mouth caused by radiation therapy in head and neck cancer patients, according to a new study by researchers at the Stanford University School of Medicine.

Ice cream funds research showing new strategy against thyroid cancer

May 21, 2018
Anaplastic thyroid cancer is almost uniformly fatal, with an average lifespan of about 5 months after diagnosis. And standard treatment for the condition includes 7 weeks of radiation, often along with chemotherapy.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.